- Home
- CWK vs APLS Comparison
CWK vs APLS Comparison
Compare CWK & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CWK
- APLS
- Stock Information
- Founded
- CWK 1784
- APLS 2009
- Country
- CWK United States
- APLS United States
- Employees
- CWK N/A
- APLS N/A
- Industry
- CWK Real Estate
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- CWK Finance
- APLS Health Care
- Exchange
- CWK Nasdaq
- APLS Nasdaq
- Market Cap
- CWK 3.4B
- APLS 3.5B
- IPO Year
- CWK 2018
- APLS 2017
- Fundamental
- Price
- CWK $16.59
- APLS $25.40
- Analyst Decision
- CWK Buy
- APLS Buy
- Analyst Count
- CWK 7
- APLS 20
- Target Price
- CWK $15.50
- APLS $34.11
- AVG Volume (30 Days)
- CWK 2.1M
- APLS 2.1M
- Earning Date
- CWK 11-03-2025
- APLS 11-04-2025
- Dividend Yield
- CWK N/A
- APLS N/A
- EPS Growth
- CWK 1003.63
- APLS N/A
- EPS
- CWK 0.87
- APLS N/A
- Revenue
- CWK $9,742,200,000.00
- APLS $754,649,000.00
- Revenue This Year
- CWK $6.81
- APLS $20.59
- Revenue Next Year
- CWK $5.87
- APLS N/A
- P/E Ratio
- CWK $18.93
- APLS N/A
- Revenue Growth
- CWK 4.63
- APLS 20.02
- 52 Week Low
- CWK $7.64
- APLS $16.10
- 52 Week High
- CWK $16.66
- APLS $39.51
- Technical
- Relative Strength Index (RSI)
- CWK 69.19
- APLS 45.71
- Support Level
- CWK $15.88
- APLS $27.26
- Resistance Level
- CWK $16.61
- APLS $28.97
- Average True Range (ATR)
- CWK 0.45
- APLS 1.00
- MACD
- CWK -0.06
- APLS -0.53
- Stochastic Oscillator
- CWK 96.39
- APLS 13.98
About CWK Cushman & Wakefield plc
Cushman & Wakefield is one of the largest commercial real estate services firms in the world, with global headquarters in Chicago. The firm provides various real estate-related services to owners, occupiers, and investors. These include brokerage services for leasing and capital markets sales as well as advisory services such as valuation, project management, and facilities management.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.